原始出處紀錄
Sanofi 通知 Nurix 決定終止 SAR448272 的第 1 期試驗並終止該計畫。Nurix 將不會收到此資產的任何未來里程碑付款或權利金,但仍符合合作計畫下其他計畫的資格。
nrix-20261103 0001549595 false 11/3/2026 1600 Sierra Point Parkway Brisbane California 0001549595 2026-11-03 2026-11-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 8-K ___________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2026 ___________________________________________ NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) ___________________________________________ Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.) 1600 Sierra Point Parkway , Brisban